Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma

Trial Profile

Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Romidepsin (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms RomiCar
  • Most Recent Events

    • 04 Aug 2016 Planned End Date changed from 1 Feb 2016 to 13 Jul 2020.
    • 04 Nov 2015 Accrual till date is 5% according to United Kingdom Clinical Research Network record
    • 01 Nov 2015 Accrual till date is 3% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top